All In Biotech

Drug Trial Radar · NCT01358877

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,804 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,804

Actual

Start

Nov 8, 2011

Primary completion

Dec 19, 2016

Study completion Nov 28, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Genentech, Inc.; Breast International Group
First posted
May 24, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

Conditions

  • Breast Cancer

Interventions

  • 5-FluorouracilDrug

    5-Fluorouracil will be administered as per the schedule specified in the respective arm.

  • CarboplatinDrug

    Carboplatin will be administered as per the schedule specified in the respective arm.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered as per the schedule specified in the respective arm.

  • DocetaxelDrug

    Docetaxel will be administered as per the schedule specified in the respective arm.

  • DoxorubicinDrug

    Doxorubicin will be administered as per the schedule specified in the respective arm.

  • EpirubicinDrug

    Epirubicin will be administered as per the schedule specified in the respective arm.

  • PaclitaxelDrug

    Paclitaxel will be administered as per the schedule specified in the respective arm.

  • PertuzumabDrug

    Pertuzumab will be administered as per the schedule specified in the respective arm.

  • PlaceboDrug

    Placebo will be administered as per the schedule specified in the respective arm.

  • TrastuzumabDrug

    Trastuzumab will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory FindingsTime frame: Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
  2. Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory FindingsTime frame: 3 years

Locations

546 sites in 42 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute ? Bisgrove

    Scottsdale, Arizona

  • Providence Regional Medical Center

    Everett, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • Kaiser Permanente - Hayward

    Hayward, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Kaiser Permanente - Oakland

    Oakland, California

  • Kaiser Permanente - Roseville

    Roseville, California

  • Sutter Cancer Center

    Sacramento, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • Southern California Kaiser Permanente

    San Diego, California

  • K. Permanente - San Fransisco

    San Francisco, California

  • K. Permanente - San Jose

    San Jose, California

  • K. Permanente - Santa Clara

    Santa Clara, California

  • K. Permanente - S. San Fran

    South San Francisco, California

  • Kaiser Permanente

    Vallejo, California

  • K. Permanente - Walnut Creek

    Walnut Creek, California

  • Rocky Mountain Cancer Center - Denver

    Denver, Colorado

  • Lutheran Hematology &Oncology

    Wheat Ridge, Colorado

  • Eastern Ct Hema/Onco Assoc

    Norwich, Connecticut

  • Washington Cancer Institute at MedStar Washington Hospital Center.

    Washington D.C., District of Columbia

  • Georgetown U

    Washington D.C., District of Columbia

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Memorial Cancer Institute

    Hollywood, Florida

  • Mayo Clinic-Jacksonville

    Jacksonville, Florida

  • Cancer Specialists

    Jacksonville, Florida

  • Ocala Oncology Center

    Ocala, Florida

  • Memorial Breast Cancer Center

    Pembroke Pines, Florida

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Florida Cancer Specialists, Research Department

    West Palm Beach, Florida

  • Phoebe Putney Memorial Hospital

    Albany, Georgia

  • Georgia Cancer Specialists

    Atlanta, Georgia

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia

  • Kootenai Cancer Center

    Post Falls, Idaho

  • Rush University Medical Center

    Chicago, Illinois

  • Uni of Chicago

    Chicago, Illinois

  • Ingalls Memorial Hospital

    Harvey, Illinois

  • Loyola University Med Center

    Maywood, Illinois

  • Edward Cancer Center Naperville

    Naperville, Illinois

Showing 40 of 546 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.